SCIENTIFIC PROGRAMME
Thursday, March 12, 2026
08.30 Registration Opens
​​
09.30 - 09.40 Welcome Addresses
Welcome Address by the conference president Michael von Bergwelt, Munich, Germany
​​
09.40 – 11.10 Plenary Session 1: Tumor immunology evolving
​
09.40 – 10.10
01.01. How T cells see neoepitopes
Stefanie Spranger, Cambridge, MA, United States
​
10.10 – 10.40
01.02. Metabolic control of T cells
Max Mazone, Leuven, Belgium
​
10.40 – 11.10
01.03. Th17 cells in cancer immunology
Karen Dixon, Basel, Switzerland
​
11.10 – 11.40 Coffee Break
​
11.40 – 13.10 Plenary Session 2: Resistance mechanisms to immunooncological agents and how to break them
​
11.40 – 12.10
02.01. Transfer tumoral mitochondria to T cells as tumor evasion mechanism
Yosuke Togashi, Okayama, Japan
​
12.10 – 12.40
02.02. On Tregs and how they can be properly targeted
Sergio Quezada, London, United Kingdom
​
12.40 – 13.10
02.03. Rewiring immune suppression at local and distant sites
Maria Sibilia, Vienna, Austria
​
13.10 – 13.40 Satellite Symposium – Slot 1
​
13.40 – 15.00 Lunch & Poster Viewing
15.00 – 17.00 Plenary Session 3: New targets and new leads
​
15.00 – 15.30
03.01. New IO leads
Ana Anderson, Boston, MA, United States
15.30 – 16.00
03.02. Expect the unexpected modulating Nacl in cancer immunotherapy
Christina Zielinski, Jena, Germany
​
16.00 – 16.30
03.03. Current status of immunotherapy in breast cancer
Nadia Harbeck, Munich, Germany
​
16.30 – 16.45 | 03.05. Talk from Submitted Abstracts
16.45 – 17.00 | 03.06. Talk from Submitted Abstracts
​
17.00 – 18.00 Plenary Session 4: Anti-cancer vaccines
​
17.00-17.30
04.01. Dark genome-derived antigens as therapeutic targets
Bernie Fox, Portland, OR, United States
​
17.30-18.00
04.02. How skin dendritic cells can be harnessed for better vaccine efficacy
Patrizia Stoitzner, Innsbruck, Austria
18.00 – 20.00 Welcome Reception and Poster Viewing (at the venue)
​
​
Friday, March 13, 2026
​
08.00 – 09.00 Plenary Session 5: Advances in clinical immunotherapy of multiple myeloma – Part I
Chair: Sebastian Theurich, Munich, Germany & tba
​​
08.00 – 08.30
05.01. Predictors of response and resistance to immunotherapies against multiple myeloma
Maximilian Merz, Leipzig, Germany
​​
08.30 – ​09.00
05.02. Dynamic changes in myeloma tissue and its microenvironment as modulators and predictors of tumor immune responses
Julia Frede, Munich, Germany
​
09.00 – 09.30 Plenary Session 6: Moving grounds: IO reaching earlier lines of treatment – Part I
09.00 – ​09.30
​06.01. Neoadjuvant immunotherapy in Bladder Cancer
Michiel S. van der Heijden, Amsterdam, Netherlands
​
09.30 – 10.30 Plenary Session 7: Technological advances in resolving tumor immunity
​
09.30 – 10.00
07.01. Modulating the microbiome for cancer immunotherapy
Bertrand Routy, Montreal, Canada
​​
10.00 – 10.30
07.02. Spatial transcriptomics and secretomics analysis to unravel potential therapy resistance mechanisms in esophageal cancer
Sarah Derks, Amsterdam, Netherlands
​
10.30 – 11.00 Coffee Break
​
11.00 – 12.30 Plenary Session 8: Immune engagers
11.00 – 11.30
08.01. Opportunities and Challenges of CD47 targeted therapy in cancer immunotherapy: Bispecific antibodies targeting CD47
Victor Moreno, Madrid, Spain
​
11.30 – 12.00
08.02. DLL3-CD3 bispecific antibodies in Small cell lung cancer
Rosa Nadal Rios, Seattle, WA, United States
​​
12.00 – 12.30
08.03. How to enhance bispecific antibody activity
Marion Subklewe, Munich, Germany
​
12.30 – 13.00 Satellite Symposium – Slot 2
​​
12.30 – 13.30 Satellite Symposium – Slot 3
12.30/13.30 – 14.30 Lunch & Poster Viewing
14.30 – 15.15 Plenary Session 9: Lifetime Achievement Award presented to Prof. Dr. John Haanen
09.01. Ways to engage endogenous T cell immunity to fight cancer
John Haanen, Amsterdam, Netherlands
​​
15.15 – 16.30 Plenary Session 10: Moving grounds: IO reaching earlier lines of treatment – Part II
​
15.15 – 15.45
10.01. Adjuvant IO is no more? Curing with neoadjuvant concepts: an overview
Alexander Eggermont, Utrecht, Netherlands
​​
15.45 - 16.15 Plenary Session 11: Advances in clinical immunotherapy of multiple myeloma – Part II
​
15.45 – 16.15
11.01. The evolving landscape of myeloma immunotherapy
Djordje Atanackovic, Baltimore, MD, United States
​
16.15 – 16.30 | 11.02. Talk from Submitted Abstracts
​
16.30 – 17.00 Coffee Break
​
17.00 – 18.00 Plenary Session 12: Young Researcher Session (from submitted abstracts)
​​
17.00 – 17.15 | 12.01. Talk from Submitted Abstracts
17.15 – 17.30 | 12.02. Talk from Submitted Abstracts
17.30 – 17.45 | 12.03. Talk from Submitted Abstracts
17.45 – 18.00 | 12.04. Talk from Submitted Abstracts
​
​
18.05 – 19.00 Poster Viewing with Presenters
19.30 ITOC12 Conference Dinner
​
​
Saturday, March 14, 2026
​​
09.00 – 10.30 Plenary Session 13: Immunooncology in gynecologic oncology
​
09.00 – 09.30
13.01. New immunooncological approaches in endometrial cancer​
Fabian Trillsch, Munich, Germany
​​​​
09.30 - 10.00
13.02. Immunotherapy of Ovarian Cancer
Frederik Marmé, Mannheim, Germany
​​
10.00 – 10.15 | 13.03. Talk from Submitted Abstracts
10.15 – 10.30 | 13.04. Talk from Submitted Abstracts
​​​
10.30 – 11.30 Plenary Session 14: Cellular therapies beyond T cells
​​
10.30 – 11.00
14.01. IPSC as universal source of therapeutic cells
Maria Themeli, Amsterdam, Netherlands
​​
11.00 – 11.30
14.02. Transient immune cell engineering: sufficient with innate help?
Andrea Ablasser, Lausanne, Switzerland
​
11.30 – 12.00 Coffee Break
​
12.00 – 13.30 Plenary Session 15: CAR- and TCR- engineered T cells
​​
12.00 – 12.30
15.01. CRISPR engineering of T cells for cancer therapy
Franziska Bläschke, Heidelberg, Germany
12.30 – 13.00
15.02. TCR T cells against novel targets
Johanna Olweus, Oslo, Norway
​
13.00 – 13.15 | 15.03. Talk from Submitted Abstracts
13.15 – 13.30 | 15.04. Talk from Submitted Abstracts
13.30 – 13.45 | 15.05. Talk from Submitted Abstracts
​​
13.45 – 14.15 Plenary Session 16: Best Poster Awards & Closing Remarks
​
14.15 – 15.00 Lunch & Farewell
​
​